Brief: Coya Therapeutics’ Coya 301 Halted Cognitive Decline In Open Label Study In Patients With Alzheimer’S
16/05/2023 12:05
May 16 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS’ COYA 301 INCREASED TREG FUNCTION AND
HALTED
COGNITIVE DECLINE IN AN OPEN LABEL STUDY IN PATIENTS WITH
ALZHEIMER’S DISEASE
* COYA THERAPEUTICS - TREATMENT WITH COYA 301 RESULTED IN
SIGNIFICANT IMPROVEMENT IN COGNITIVE FUNCTION, AS MEASURED BY
MINI-MENTAL STATE EXAMINATION TEST
* COYA THERAPEUTICS INC - TREATMENT WITH COYA 301 APPEARED
TO BE
WELL TOLERATED IN PATIENTS WITH AD
* COYA THERAPEUTICS INC - NO SERIOUS ADVERSE EVENTS WERE
REPORTED,
AND NO PATIENT DISCONTINUED STUDY
Source text for Eikon: ID:nBw8K7Xxta
Further company coverage: COYA.O
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)